Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 745.27

+1.1%

10:41 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (2191)	8/29/2017 7:11:47 PM
From: Miljenko Zuanic	Read Replies (1) of 3559

Another question: When antibody R&D end, can Sanofi lunch hostile take-over? IF REGN is capable to extend Eylea LIFE beyond 2022/23 (by hard to make bio-similar and/or Ang2-co-formulation), it will be reach cash generator for some time that even significant premium to price that Sanofi is paying today would be almost sure. Without any other drugs revenue. The significant "uncertainty" to this outcome is price control issue and off-label avastin! Sooner or later this issue will surface, I am afraid.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next